Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Aurobindo Pharma Ltd.
Swot
Aurobindo Pharma Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Aurobindo Pharma Ltd. has 15 Strengths, 6 Weaknesses, 5 Opportunities and 4 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(15)
Weakness
(6)
Opportunity
(5)
Threats
(4)
Others
(3)
Benjamin Graham Value Screen
Consistent Highest Return Stocks over Five Years
Mid-range Performer (DVM)
Rising Net Cash Flow and Cash from Operating activity
PEG lower than Industry PEG
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Growth in Net Profit with increasing Profit Margin (QoQ)
Companies with Low Debt
Increasing Revenue every quarter for the past 3 quarters
Increasing profits every quarter for the past 2 quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with decreasing Promoter pledge
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Weak Momentum: Price below Short, Medium and Long Term Averages
RSI indicating price weakness
High promoter stock pledges
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter
Brokers upgraded recommendation or target price in the past three months
Big Deal (Insider and SAST) buys last month greater than 1% of total shares
Street Favorite: High Analyst Rating with at least 20% upside
FII / FPI or Institutions increasing their shareholding
MFs increased their shareholding last quarter
Red Flags: Firms linked to ongoing regulatory investigations/legal cases
Broker downgrades in price or recommendation in the past one month
US FDA Warning Letter
Red Flag: Companies seeing significant coronavirus impact
Rising Delivery Percentage Compared to Prev Day
Indian stocks that could be impacted by Brexit (Britain leaving the EU)
Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks
